397328-86-8Relevant articles and documents
Brain Penetrable Histone Deacetylase 6 Inhibitor SW-100 Ameliorates Memory and Learning Impairments in a Mouse Model of Fragile X Syndrome
Kozikowski, Alan P.,Shen, Sida,Pardo, Marta,Tavares, Maurício T.,Szarics, Dora,Benoy, Veronick,Zimprich, Chad A.,Kutil, Zsófia,Zhang, Guiping,Ba?inka, Cyril,Robers, Matthew B.,Van Den Bosch, Ludo,Eubanks, James H.,Jope, Richard S.
, p. 1679 - 1695 (2019/01/04)
Disease-modifying therapies are needed for Fragile X Syndrome (FXS), as at present there are no effective treatments or cures. Herein, we report on a tetrahydroquinoline-based selective histone deacetylase 6 (HDAC6) inhibitor SW-100, its pharmacological a
TRICYCLIC PYRAZOLOPYRIDINE COMPOUNDS
-
Paragraph 0124, (2015/11/27)
In one aspect this invention relates generally to compounds of Formula I and sub-formulas thereof, or a tautomer of each thereof, a pharmaceutically acceptable salt of each thereof, or a pharmaceutically acceptable solvate of each of the foregoing, where
PYRAZOLOPYRIDINE PYRAZOLOPYRIMIDINE AND RELATED COMPOUNDS
-
Paragraph 0265; 0266, (2015/11/25)
In one aspect this invention relates generally to compounds of Formula: and sub-formulas thereof, or a tautomer of each thereof, a pharmaceutically acceptable salt of each thereof, or a pharmaceutically acceptable solvate of each of the foregoing, where X1, L1, L3, and R3 are described herein.
THERAPEUTIC INHIBITORY COMPOUNDS
-
Page/Page column 198, (2015/07/16)
The invention provides compounds of Formula I and Formula II: A-B-C-D-E-F-G-J (I) C-D-E-F-G-J (II) wherein A, B, C, D, E, F, G, and J have any of the values defined in the specification, and salts thereof. The compounds are useful for inhibiting plasma kallikrein, and for treating a disease or condition in an animal where inhibition of plasma kallikrein is indicated.
HDAC INHIBITORS AND THERAPEUTIC METHODS USING THE SAME
-
Page/Page column 67, (2012/08/27)
Histone deacetylases inhibitors (HDACIs) and compositions containing the same are disclosed. Methods of treating diseases and conditions wherein inhibition of HDAC provides a benefit, like a cancer, a neurodegenerative disorder, a peripheral neuropathy, a neurological disease, traumatic brain injury, stroke, hypertension, malaria, an autoimmune disease, autism, autism spectrum disorders, and inflammation, also are disclosed.
Pyrrolidin-3-yl-N-methylbenzamides as potent histamine 3 receptor antagonists
Zhou, Dahui,Gross, Jonathan L.,Sze, Jean Y.,Adedoyin, Adedayo B.,Bowlby, Mark,Di, Li,Platt, Brian J.,Zhang, Guoming,Brandon, Nicholas,Comery, Thomas A.,Robichaud, Albert J.
scheme or table, p. 5957 - 5960 (2011/10/18)
On the basis of the previously reported benzimidazole 1,3′- bipyrrolidine benzamides (1), a series of related pyrrolidin-3-yl-N- methylbenzamides were synthesized and evaluated as H3 receptor antagonists. In particular, compound 32 exhibits pot
AZACYCLYLBENZAMIDE DERIVATIVES AS HISTAMINE-3 ANTAGONISTS
-
Page/Page column 40, (2009/01/20)
The present invention provides a compound of formula I and the use thereof for the treatment of a central nervous system disorder related to or affected by the histamine-3 receptor
